PedvaxHIB is a vaccine that protects infants and young children against Haemophilus influenzae type b (Hib), a bacterium that can cause meningitis, pneumonia, and other serious infections. Made by Merck, it stands out from other Hib vaccines because it requires fewer doses to complete the series: three shots total, compared to four with other brands.
What PedvaxHIB Protects Against
Hib bacteria can invade the bloodstream, the lining of the brain, the lungs, and other parts of the body. Before routine vaccination began in the late 1980s, Hib was the leading cause of bacterial meningitis in children under five. The infection could also cause epiglottitis (a dangerous swelling in the throat), septic arthritis, and pneumonia. Infants and toddlers are most vulnerable because their immune systems haven’t yet learned to fight off bacteria with the sugary outer coating that Hib carries.
PedvaxHIB works by linking a piece of that sugar coating to a protein from another bacterium. This combination trains the infant’s immune system to recognize and attack Hib. Without the protein attachment, young immune systems struggle to respond to the sugar coating alone.
How the Dosing Schedule Works
PedvaxHIB uses a two-dose primary series plus a booster, for three shots total:
- First dose: 2 months of age
- Second dose: 4 months of age
- Booster dose: 12 through 15 months of age
Other Hib vaccines, such as ActHIB and Hiberix, require a three-dose primary series (at 2, 4, and 6 months) plus a booster, totaling four shots. That one fewer visit is a practical advantage for families and clinics alike.
Fewer Doses Than Other Hib Vaccines
The reason PedvaxHIB can skip the 6-month dose comes down to its design. The protein it uses as a carrier tends to produce a strong immune response earlier in infancy than the carriers used in ActHIB or Hiberix. Two primary doses are enough to build a foundation of protection before the booster reinforces it around the first birthday.
This characteristic has made PedvaxHIB particularly important for populations at higher risk of early Hib disease. In 2024, the Advisory Committee on Immunization Practices updated its recommendations specifically for American Indian and Alaska Native infants, who face elevated rates of Hib infection in the first months of life. For these communities, getting strong protection after just two doses rather than three matters.
Mixing Brands During the Series
All monovalent Hib vaccines are considered interchangeable. A series that mixes brands will still produce protective antibody levels. However, there’s one important catch: if your child receives different brands at the 2-month and 4-month visits, a third primary dose at 6 months is needed regardless of which brands were used. The two-dose primary schedule only applies when PedvaxHIB is used for both early doses.
Any brand of Hib vaccine can be used for the booster at 12 to 15 months, no matter what was given during the primary series.
Common Side Effects
Side effects from PedvaxHIB are typical of childhood vaccines and generally mild. The most common reactions include redness, warmth, or swelling at the injection site, along with fever and irritability. These usually resolve within a day or two.
Severe allergic reactions are rare but possible with any vaccine. Signs include hives, swelling of the face or throat, difficulty breathing, rapid heartbeat, and dizziness. These symptoms would appear within minutes to hours after vaccination.
Practical Details for Parents
Unlike ActHIB and Hiberix, which come as a powder that needs to be mixed with a liquid before injection, PedvaxHIB is supplied as a ready-to-use liquid. This simplifies preparation and reduces the chance of errors during administration. The vaccine is stored in a standard refrigerator between 36°F and 46°F, the same range used for most childhood vaccines.
PedvaxHIB is given as an intramuscular injection, typically in the thigh for infants. It can be administered during the same visit as other routine childhood vaccines without affecting how well any of them work.